By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market Tuesday that it has renewed its 10-year strategic partnership with One Lambda.

The alliance, which began in 2000, is focused on developing platforms and technologies for human leukocyte antigen typing and antibody screening for the organ transplantation market. One Lamda has developed a range of HLA tests based on Luminex's xMAP technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.